{"id":1677,"date":"2014-05-26T15:05:48","date_gmt":"2014-05-26T13:05:48","guid":{"rendered":"http:\/\/backup.altanalaw.com\/\/?p=1677"},"modified":"2014-05-26T15:05:48","modified_gmt":"2014-05-26T13:05:48","slug":"bioalliance-pharma","status":"publish","type":"post","link":"https:\/\/backup.altanalaw.com\/en\/medias\/bioalliance-pharma","title":{"rendered":"BIOALLIANCE PHARMA"},"content":{"rendered":"<p><\/p>\n<p>ALTANA advised BIOALLIANCE PHARMA in its cross-border corporate merger with TOPOTARGET, a Danish biotech company, to create a leader in orphan oncology disease treatments. Each of the two companies have more than 8,000 shareholders and the market capitalization of the combined entity will exceed \u20ac200 million. This merger is the first-ever cross border merger of a French listed company with a listed company of a different nationality under the 2005 merger Directive.<\/p>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>ALTANA advised BIOALLIANCE PHARMA in its cross-border corporate merger with TOPOTARGET, a Danish biotech company, to create a leader in orphan oncology disease treatments. Each of the two companies have more than 8,000 shareholders and the market capitalization of the combined entity will exceed \u20ac200 million. This merger is the first-ever cross border merger of [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1677","post","type-post","status-publish","format-standard","hentry","category-medias","expertise-droit-societes-fusions-acquisitions"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BIOALLIANCE PHARMABIOALLIANCE PHARMA - Advant Altana<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIOALLIANCE PHARMABIOALLIANCE PHARMA - Advant Altana\" \/>\n<meta property=\"og:description\" content=\"ALTANA advised BIOALLIANCE PHARMA in its cross-border corporate merger with TOPOTARGET, a Danish biotech company, to create a leader in orphan oncology disease treatments. Each of the two companies have more than 8,000 shareholders and the market capitalization of the combined entity will exceed \u20ac200 million. This merger is the first-ever cross border merger of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma\" \/>\n<meta property=\"og:site_name\" content=\"Advant Altana\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-26T13:05:48+00:00\" \/>\n<meta name=\"author\" content=\"Altana Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Altana Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma\",\"url\":\"https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma\",\"name\":\"BIOALLIANCE PHARMABIOALLIANCE PHARMA - Advant Altana\",\"isPartOf\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#website\"},\"datePublished\":\"2014-05-26T13:05:48+00:00\",\"dateModified\":\"2014-05-26T13:05:48+00:00\",\"author\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/backup.altanalaw.com\/#website\",\"url\":\"https:\/\/backup.altanalaw.com\/\",\"name\":\"Advant Altana\",\"description\":\"Soci\u00e9t\u00e9 d&#039;avocats \u00e0 la Cour de Paris\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/backup.altanalaw.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\",\"name\":\"Altana Communication\",\"url\":\"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIOALLIANCE PHARMABIOALLIANCE PHARMA - Advant Altana","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"BIOALLIANCE PHARMABIOALLIANCE PHARMA - Advant Altana","og_description":"ALTANA advised BIOALLIANCE PHARMA in its cross-border corporate merger with TOPOTARGET, a Danish biotech company, to create a leader in orphan oncology disease treatments. Each of the two companies have more than 8,000 shareholders and the market capitalization of the combined entity will exceed \u20ac200 million. This merger is the first-ever cross border merger of [&hellip;]","og_url":"https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma","og_site_name":"Advant Altana","article_published_time":"2014-05-26T13:05:48+00:00","author":"Altana Communication","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Altana Communication","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma","url":"https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma","name":"BIOALLIANCE PHARMABIOALLIANCE PHARMA - Advant Altana","isPartOf":{"@id":"https:\/\/backup.altanalaw.com\/#website"},"datePublished":"2014-05-26T13:05:48+00:00","dateModified":"2014-05-26T13:05:48+00:00","author":{"@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/backup.altanalaw.com\/medias\/bioalliance-pharma"]}]},{"@type":"WebSite","@id":"https:\/\/backup.altanalaw.com\/#website","url":"https:\/\/backup.altanalaw.com\/","name":"Advant Altana","description":"Soci\u00e9t\u00e9 d&#039;avocats \u00e0 la Cour de Paris","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/backup.altanalaw.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6","name":"Altana Communication","url":"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm"}]}},"_links":{"self":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/1677"}],"collection":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/comments?post=1677"}],"version-history":[{"count":0,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/1677\/revisions"}],"wp:attachment":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/media?parent=1677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/categories?post=1677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/tags?post=1677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}